Geoffrey Liu
Impact in
- Cancer Research top 0.2%
- Cancer Genomics and Diagnostics
- Pulmonary and Respiratory Medicine top 0.05%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 169
- Lung Cancer Research Studies 36
-
- Lung Cancer Treatments and Mutations 124
- Lung Cancer Diagnosis and Treatment 33
- Co-authors
- Ming‐Sound Tsao (89 shared papers)David Christiani (67 shared papers)Frances Alice Shepherd (85 shared papers)John C. Wain (45 shared papers)Thomas James Lynch (41 shared papers)Wei Zhou (33 shared papers)Chang‐Qi Zhu (10 shared papers)Margaret I. Fitch (1 shared paper)
- Journals
- Lung Cancer (37 papers)Journal of Thoracic Oncology (35 papers)Journal of Clinical Oncology (26 papers)Clinical Cancer Research (23 papers)Annals of Oncology (23 papers)
- Partner nations
- CanadaUnited StatesChina
In The Last Decade
Geoffrey Liu
801 papers receiving 36.8k citations
Geoffrey Liu's Hit Papers
Peers
Comparison fields: 5 of 224
- Cancer Research 5.4k
- Pulmonary and Respiratory Medicine 11.6k
- Oncology 9.2k
- Otorhinolaryngology 778
- Molecular Biology 9.9k
Countries citing papers authored by Geoffrey Liu
This map shows the geographic impact of Geoffrey Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Geoffrey Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Geoffrey Liu more than expected).
Fields of papers citing papers by Geoffrey Liu
This network shows the impact of papers produced by Geoffrey Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Geoffrey Liu. The network helps show where Geoffrey Liu may publish in the future.
Co-authors
The 25 scholars most cited alongside Geoffrey Liu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 846 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome Hit paper breakdown → | 2005 | 1605 |
| 2 | Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer Hit paper breakdown → | 2014 | 1236 |
| 3 | Probability of Cancer in Pulmonary Nodules Detected on First Screening CT Hit paper breakdown → | 2013 | 1068 |
| 4 | A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25 Hit paper breakdown → | 2008 | 1040 |
| 5 | Patient preferences for oral versus intravenous palliative chemotherapy. Hit paper breakdown → | 1997 | 824 |
| 6 | First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer Hit paper breakdown → | 2020 | 804 |
| 7 | Sensitive tumour detection and classification using plasma cell-free DNA methylomes Hit paper breakdown → | 2018 | 706 |
| 8 | Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study Hit paper breakdown → | 2017 | 610 |
| 9 | Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Hit paper breakdown → | 2008 | 594 |
| 10 | Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes Hit paper breakdown → | 2017 | 504 |
| 11 | Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial Hit paper breakdown → | 2017 | 471 |
| 12 | Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial Hit paper breakdown → | 2016 | 402 |
| 13 | 2010 | 382 | |
| 14 | Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer Hit paper breakdown → | 2014 | 363 |
| 15 | 2019 | 329 | |
| 16 | 2007 | 281 | |
| 17 | 2015 | 276 | |
| 18 | The adoption of artificial intelligence in employee recruitment: The influence of contextual factors Hit paper breakdown → | 2021 | 273 |
| 19 | 2004 | 261 | |
| 20 | 2013 | 257 |
About Geoffrey Liu
Geoffrey Liu is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Otorhinolaryngology and Molecular Biology, having authored 846 papers that have together received 37.7k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (124 papers), Esophageal Cancer Research and Treatment (50 papers), Cancer Genomics and Diagnostics (43 papers), Head and Neck Cancer Studies (42 papers), RNA modifications and cancer (41 papers), Genetic Associations and Epidemiology (36 papers), Lung Cancer Research Studies (36 papers) and Lung Cancer Diagnosis and Treatment (33 papers). The work is most often cited by research in Cancer Research (5.4k citations), Pulmonary and Respiratory Medicine (11.6k citations), Oncology (9.2k citations), Otorhinolaryngology (778 citations) and Molecular Biology (9.9k citations). Geoffrey Liu has collaborated with scholars based in Canada, United States and China. Frequent co-authors include Ming‐Sound Tsao, David Christiani, Frances Alice Shepherd, John C. Wain, Thomas James Lynch, Wei Zhou, Chang‐Qi Zhu, Margaret I. Fitch, E Warner and E. Franssen. Their work appears in journals such as Lung Cancer, Journal of Thoracic Oncology, Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.